单剂量利福平对健康志愿者氟伐他汀药代动力学的影响
本研究在10名健康受试者中开展交叉试验,比较单用氟伐他汀20 mg口服与先静脉输注利福平600 mg(30分钟)后的药代动力学。结果显示利福平使氟伐他汀AUC0-∞均值增加255%、Cmax均值增加254%,口服分布容积均值降低71%,而T1/2、MAT和Tpeak无显著变化,提示利福平通过抑制肝细胞OATP转运体产生显著药物相互作用。
要点
- 利福平使氟伐他汀AUC0-∞均值增加255%、Cmax均值增加254%。
- 利福平使氟伐他汀口服分布容积均值降低71%。
- 氟伐他汀T1/2、MAT和Tpeak无显著变化。
核心结论
- 利福平与氟伐他汀存在显著药物相互作用,机制可能为抑制肝细胞OATP转运体。
研究设计与样本
- 在10名健康受试者中开展交叉研究,随机分两期接受氟伐他汀20 mg口服单用或先静脉输注利福平600 mg(30分钟)。
主要发现
- 静脉利福平使氟伐他汀AUC0-∞均值增加255%。
- 静脉利福平使氟伐他汀Cmax均值增加254%。
- 静脉利福平使氟伐他汀口服分布容积均值降低71%。
- 氟伐他汀的T1/2、MAT和Tpeak无显著变化。
临床怎么用
- 临床联用利福平与氟伐他汀时需警惕氟伐他汀暴露量显著升高,关注相关不良反应风险。
局限性
- 研究样本为10名健康受试者,结论外推至患者人群需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of this study was to determine the effects of the OATP inhibitor rifampin on pharmacokinetic of Biopharmaceutics Drug Disposition Classification System Class 1 compound fluvastatin. A crossover study was carried out in 10 healthy subjects who were randomized to 2 phases to receive fluvastatin 20 mg orally alone and following a 30-minute 600 mg i.v. infusion of rifampin. The results demonstrated that i.v. rifampin increased the mean area under the plasma fluvastatin concentration-time curve (AUC0-∞ ) by 255%, mean peak plasma concentration (Cmax ) by 254%, decreased oral volume of distribution by 71%, whereas the mean elimination terminal half-life (T1/2 ), mean absorption time (MAT), and time to peak concentration (Tpeak ) of fluvastatin did not significantly change. The study demonstrated that rifampin exhibited a significant drug interaction with fluvastatin. The mechanism of the increased plasma concentrations is likely due to inhibition of OATP transporters in hepatocytes.
引用
- Xiang Y, Okochi H, Kozachenko I, et al. Effects of Single Dose Rifampin on the Pharmacokinetics of Fluvastatin in Healthy Volunteers. Clin Pharmacol Ther. 2021. PMID: 33880760. doi:10.1002/cpt.2268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。